Axantia to market Lupin’s pegfilgrastim in the Middle East and North Africa

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Axantia to market Lupin’s pegfilgrastim in the Middle East and North Africa

Home/Pharma News | Posted 25/02/2022 0 Post your comment

On 1 February 2022, Indian multinational pharmaceutical company Lupin Ltd announced that it was entering into a License, Supply and Technology Sharing agreement with Axantia, to market Lupin’s pegfilgrastim biosimilar in certain territories in the Middle East and North Africa.

Under the terms of the agreement, Axantia will register, distribute and market Lupin’s pegfilgrastim in Middle Eastern and North African territories, including Saudi Arabia, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria. Axantia will operate through its pharmaceutical subsidiaries – Pharma International Company and Med City Pharmaceutical Industries.

Lupin’s pegfilgrastim product is a biosimilar version of Amgen’s originator Neulasta. Pegfilgrastim stimulates the production of neutrophils and can be used to prevent infection in patients with reduced neutrophil count, such as those receiving chemotherapy.

The US Food and Drug Administration (FDA) accepted Lupin’s Biologics License Application (BLA) for the pegfilgrastim biosimilar in June 2021 [1]. Lupin also hopes to soon launch their etanercept biosimilar in the US [2].

This new agreement comes following Lupin’s December 2021 agreement with Biomm SA, to distribute and market Lupin’s pegfilgrastim biosimilar in Brazil [3].

Etanercept biosimilar injection pen, YLB113, convenient and easy to use

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: Nomenclatura de biológicos y biosimilares en Brasil Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: Nomenclatura de biológicos y biosimilares en Brasil !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA accepts application for Lupin’s pegfilgrastim biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 25]. Available from: www.gabionline.net/biosimilars/news/fda-accepts-application-for-lupin-s-pegfilgrastim-biosimilar
2. GaBI Online - Generics and Biosimilars Initiative. Lupin to launch etanercept and pegfilgrastim biosimilars in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 25]. Available from: www.gabionline.net/biosimilars/news/Lupin-to-launch-etanercept-and-pegfilgrastim-biosimilars-in-the-US
3. GaBI Online - Generics and Biosimilars Initiative. Lupin forms partnership to market pegfilgrastim biosimilar in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 25]. Available from: www.gabionline.net/biosimilars/news/lupin-forms-partnership-to-market-pegfilgrastim-biosimilar-in-brazil

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.